Micronoma raises $ 3.5 million in convertible note financing
SAN DIEGO, February 17, 2021 / PRNewswire / – Micronome, the first cancer detection biotechnology company to use signals from the tumor-bound microbiome to diagnose early-stage cancer with liquid biopsy technology, today announced the closing of $ 3.5 million in the financing of convertible debt. Contributions came from existing investor, SymBiosis, LLC, based in the United States, and new European investor, The Seerave Foundation. The investments bring the total amount of Micronoma funding to $ 6.5 million since the company’s first round of funding six months ago.
The micronoma decrypts the signals from some of the world’s oldest material, the microbiome, to detect cancer at an early stage, from all genomes. The additional funding will allow Micronoma to complete its validation study on lung cancer prediction, implement Clinical Laboratory Improvement Amendments (CLIA) operations, establish its go-to-market strategy using its Oncobiota ™ platform and to initiate work on a second cancer target.
“The Seerave Foundation strongly supports efforts aimed at enabling personalized cancer treatments. We are convinced that the nutrition-microbiome-immune system axis is an important factor in the journey of each patient, ”said David rees, founder of the Seerave Foundation. “Thus, we recognize the early diagnosis of microbial DNA associated with cancer as a key element in transforming cancer diagnosis and treatment in the future. We are confident that the Micronoma platform will complement our other research activities and help translate scientific innovations into practical applications. We are interested in being able to improve the quality of care with a more holistic and patient-centered approach. Our ultimate goal is to move from a therapeutic framework to a preventive personalized medicine framework where Micronoma’s innovation and expertise come into play, to empower physicians with actionable biomarkers. “
Promising research from Micronoma has been published in Nature last year, showing unique predictive microbial signatures in tissue and blood for most major types of cancer. Accurate and early detection of cancer by liquid biopsy remains a challenge that Micronoma may be able to solve with its proprietary Oncobiota ™ platform. Although having the potential to be a diagnostic tool for pancreatic cancer, Micronoma will start with lung cancer and, with this recent funding, move towards the diagnosis of pancreatic cancer.
“We are grateful for the continued and new support from like-minded organizations that are as dedicated as us to finding innovative and specific ways to dramatically improve early cancer diagnosis,” said Sandrine Miller-Montgomery, CEO of Micronoma. “SymBiosis has been an amazing partner and we are very happy to now have Seerave, extending our support globally. Together, we can expand the boundaries of care and revolutionize what practitioners and patients have come to think of as the status quo. We are all very passionate. on bringing this technology to market as quickly and completely as possible. “
Each year, there are approximately 18 million new cancer cases worldwide and nine million cancer deaths. It is estimated that with early detection, up to 4 million of these deaths could be prevented each year. The diagnostic implications of microbiome markers in fluid and tissue biopsies are vast, and Micronoma is poised to lead the way in helping prevent the unnecessary suffering caused by a diagnosis of advanced cancer.
To learn more about Micronoma, visit Micronoma.com.
Micronoma is the first cancer detection company using signals from some of the world’s oldest materials, circulating microbiome signatures, to enable clinicians to diagnose cancer at an early stage using mini liquid biopsy technology. invasive. Micronoma was founded in 2019 by leaders in microbiome research with the goal of revolutionizing and advancing the practice of early cancer diagnosis and personalized treatment through sensitive microbiome techniques, ensuring that patients’ needs are met. identified and treated by their clinicians as early as possible for a better chance of living longer and healthier. The company is headquartered at San diego, california